FIELD: organic chemistry.
SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, where, independently for each case, ring A is a condensed cyclopropyl or 4–6-member heterocycloalkyl ring containing 1–2 oxygen atoms; ring B is an unsubstituted phenyl or 5–6 membered monocyclic heteroaryl ring, containing 1–2 heteroatoms selected from nitrogen and sulfur; ring C is selected from substituted phenyl or substituted pyridine, structures of which are specified in claim 1. Invention also relates to specific compounds described by formula I, a pharmaceutical composition based on described compounds, method for inhibiting voltage-dependent sodium ion channel and method of treating said diseases, based on use of compound of formula I.
EFFECT: obtaining novel heterocyclic compounds which inhibit voltage-dependent ion sodium channel NaV 1.7.
27 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | 2015 |
|
RU2695649C2 |
| RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
| PERMEABLE GLYCOSIDASE INHIBITORS AND USE THEREOF | 2013 |
|
RU2707292C2 |
| SELECTIVE GLYCOSIDASE INHIBITORS AND USE THEREOF | 2011 |
|
RU2592285C2 |
| SELECTIVE GLYCOSIDASE INHIBITORS AND USE THEREOF | 2011 |
|
RU2609210C2 |
| HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM | 2007 |
|
RU2364597C1 |
| PRODRUGS OF CONJUGATED BICYCLIC C5aR ANTAGONISTS | 2019 |
|
RU2794327C2 |
| NEW PYRROLOPYRIMIDINE COMPOUND OR ITS SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT, IN PARTICULAR, AGENT FOR PREVENTION AND / OR TREATMENT OF TUMORS AND SO ON, BASED ON INHIBITING INFLUENCE ON NAE | 2015 |
|
RU2658008C2 |
| NOVEL BENZODIOXOLS | 2003 |
|
RU2304580C2 |
| ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
